Defective antigen-presenting cell function in patients with systemic lupus erythematosus.
OBJECTIVE
Patients with systemic lupus erythematosus (SLE) who exhibit defective in vitro responses to recall antigens and normal responses to alloantigens have been shown to have an abnormality in antigen-presenting cell (APC) function. This study was undertaken to further characterize this defect in APC function in lupus patients.


METHODS
Mononuclear cells (MNC) from the peripheral blood of patients with SLE and from normal individuals were cultured in the presence of either recall antigen tetanus toxoid (TT), anti-CD3 (OKT3) monoclonal antibody, or alloantigens, and proliferative or interleukin-2 responses were assessed. Cell surface expression of B7-1 was assessed by flow cytometry.


RESULTS
MNC from all normal individuals and from 7 patients with SLE responded to both TT and alloantigen and were designated +/+. Twelve SLE patients did not respond to TT but did respond to alloantigen stimulation and were designated -/+. In both normal subjects and SLE patients, the ability to respond to OKT3 correlated strongly with the ability to respond to recall antigen. A defect in APC costimulatory function was suggested by data demonstrating that interferon-gamma-induced expression of B7-1 was significantly reduced in SLE patients compared with controls. Neither controls nor SLE patients expressed detectable amounts of surface B7-1 molecule on resting APC. Defective recall and anti-CD3-stimulated responses could be enhanced in SLE patients in the presence of B7/BBl-transfected P815 murine mastocytoma cells underscoring an SLE-associated defect in costimulatory activity. However, nontransfected P815 cells were also able to enhance responses to OKT3 in -/+ patients; blocking experiments showed that this was mediated through an IgG Fc receptor-dependent mechanism.


CONCLUSIONS
These data indicate that SLE-associated defects in APC function in vitro can be accounted for by abnormalities in APC surface membrane molecules such as B7, IgG Fc receptors, and possibly others.
Tsokos
G C
GC
Walter Reed Army Medical Center, Washington, DC 20307-5100, USA.
Kovacs
B
B
Sfikakis
P P
PP
Theocharis
S
S
Vogelgesang
S
S
Via
C S
CS
D000293:Adolescent; D000328:Adult; D000917:Antibody Formation / Q000187:drug effects; D000938:Antigen-Presenting Cells / Q000502:physiology*; D018122:B7-1 Antigen / Q000378:metabolism* / Q000494:pharmacology; D017252:CD3 Complex / Q000494:pharmacology; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology; D008180:Lupus Erythematosus, Systemic / Q000276:immunology*; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D017452:Receptors, IgG / Q000502:physiology; D013745:Tetanus Toxoid / Q000494:pharmacology
D018122:B7-1 Antigen; D017252:CD3 Complex; D007376:Interleukin-2; D017452:Receptors, IgG; D013745:Tetanus Toxoid